Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2017-06-01
2018-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carpal Tunnel Syndrome and Amyloidosis
NCT04245098
Prevalence Study of Amyloidosis in Patients With Surgery of Suspect Bilateral Carpal Tunnel (AMYLYONCARP)
NCT04890119
Carpal Tunnel Release With Risk Factors for Amyloidosis
NCT05793320
Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
NCT04611204
Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
NCT02792790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The most frequent clinical manifestations are cardiac, renal and hepatic involvement, but vary widely depending on the type of amyloidosis , organ affected and the extent of the deposits. Infiltration of amyloid may produce signs and symptoms that could be very similar to other diseases, like the rheumatologic one. This potentially polymorphous clinic presentation may suggest under-diagnosis by low clinical suspicion.
Carpal tunnel syndrome is frequent in patients with A and may be the initial manifestation. This syndrome is generated by the progressive infiltration of amyloid fibrils in the retinaculum flexor and in synovial tissue, causing compression of the medium nerve. A frequency of up to 13% of carpal tunnel syndrome has been reported in patients with primary amyloidosis.
In 1993, Breda et al. assessed 98 tendon and synovial tissue's biopsies of patients operated for carpal tunnel syndrome. The pathology revealed amyloid deposition in 12% of them, of which 8 had no evidence of systemic disease. This amyloid deposition was interpreted as probably secondary to chronic local inflammation. In 1992, Kyle et al. evaluated the incidence of systemic amyloidosis in a retrospective cohort of 35 patients with carpal tunnel syndrome and synovial local deposition of amyloidosis without evidence of systemic amyloidosis. During follow-up only 2 developed systemic amyloidosis and 11 showed only laboratory abnormalities (9 monoclonal band and 2 monoclonal light chain in the urine). In this group the amyloid deposition was identified as transthyretin (TTR) dependent in 32 of 35 cases.
Even though there are estimations regarding the prevalence of A in general populations worldwide and in patients with carpal tunnel syndrome surgery, there is no local estimation in Argentina. Additionally, it is not known if the presentation of amyloid deposits in tendon elements of pathological the carpal tunnel correlates with subcutaneous amyloid deposit.
In this project the investigators propose to estimate the prevalence of Amyloidosis in the synovial tissue of patients with surgical carpal tunnel syndrome and correlate them with deposits of amyloid in the subcutaneous cellular tissue fat.
What is the prevalence of amyloidosis, in cellular subcutaneous fat biopsy, flexor retinaculum of the carpus and synovial tissue of the flexor tendons sheath, in patients with carpal tunnel syndrome surgery?
Primary objective
1\. To estimate the prevalence of the presence of amyloid deposits in: (i) a biopsy of cellular subcutaneous fat, (ii) the flexor retinaculum of the carpus and (iii) synovial tissue of the flexor tendons sheath, with requirement for carpal tunnel surgery.
Secondary objectives
1. Detect and characterize patients with subclinical amyloidosis.
2. Identify the protein deposited in patients with amyloidosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
amyloid
unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Secondary acute carpal tunnel syndrome (eg ganglion).
* Formal contraindication surgical treatment
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Italiano de Buenos Aires
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diego Hernan Giunta, MD
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adela Aguirre, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Lourdes Posadas-Martínez, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Dorotea Fantl, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
María S. Saez, BCH
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Gustavo Greloni, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Federico Varela, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Patricia Sorroche, BCH
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Gabriel Waisman, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Fernán G. De Quiros, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Jorge Boretto, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Elsa Nucifora, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Diego Giunta, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HIBA
CABA, Buenos Aires, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1589
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.